Shares of Amgen AMGN fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the ...

Amgen shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and rocatinlimab, ...

Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment ...

Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating today. David Risinger has ...

Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...

Bank of America Securities analyst Charlie CY Yang has maintained their neutral stance on AMGN stock, giving a Hold rating today. Charlie CY ...

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...